Does ashwagandha help with sleep? What the evidence shows

Does ashwagandha help with sleep? What the evidence shows

Yes, ashwagandha appears to improve sleep quality in humans, with the most consistent evidence in adults experiencing insomnia or stress-related sleep disruption. A 2021 systematic review and meta-analysis published in *PLOS ONE* pooled five randomised controlled trials with a combined 400 participants and found ashwagandha extract produced a statistically significant, small-to-moderate improvement in overall sleep (standardised mean difference -0.59, 95% CI -0.75 to -0.42).[1] Effects were most pronounced at doses of 600 mg or more per day, in people with diagnosed insomnia, and after treatment durations of at least eight weeks. Ashwagandha is not a sedative — it does not cause drowsiness or knock-out effects — but it addresses several upstream drivers that prevent restorative sleep, particularly the HPA axis hyperactivation that keeps the brain in an alert state long after the body is exhausted. It is a slow-acting, cumulative intervention, not a single-night fix.

What is ashwagandha, and why is it used for sleep?

Ashwagandha (*Withania somnifera*) is the root of a small shrub native to India and North Africa, and is classified in traditional Ayurvedic medicine as a rasayana — a category of herbs associated with longevity, vitality, and restoration. The Latin epithet *somnifera* means "sleep-bearing," which reflects the plant's long-standing association with rest and recovery in traditional use.

Modern pharmacological research has identified a family of steroidal lactone compounds in the root called withanolides as the primary bioactive agents. These compounds act on multiple biological targets, but the two most relevant to sleep are the HPA axis — the neuroendocrine system that governs the stress response and cortisol production — and the GABAergic pathway, which is the brain's principal inhibitory signalling system and a central component of natural sleep induction.

Critically, ashwagandha is not understood to produce sleep by sedating the nervous system. Its mechanism is better described as removing obstacles to sleep: reducing the chronic cortisol elevation that sustains hyperarousal, and modulating inhibitory neurotransmitter activity in a way that quietens neuronal excitability. The distinction matters clinically, because a sedative and an adaptogen will perform differently across populations and conditions.

What does the HPA axis have to do with sleep quality?

The hypothalamic-pituitary-adrenal axis is the body's primary stress response system. In response to perceived threat or demand, the hypothalamus releases corticotropin-releasing hormone (CRH), which triggers the pituitary to release adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal glands to release cortisol. Cortisol promotes alertness, mobilises energy, and suppresses non-essential functions — including the physiological transitions that prepare the body for sleep.

In a healthy individual, cortisol follows a clear diurnal curve: it peaks in the morning (the cortisol awakening response, a feature of normal HPA axis function), then declines steadily through the day, reaching its lowest point around 2 to 3am. This declining evening trajectory is a necessary condition for sleep onset and for the consolidation of slow-wave sleep. When chronic stress keeps the HPA axis activated, the evening decline is blunted. A 2022 systematic review and meta-analysis from the University of Freiburg, pooling data from 20 case-control studies with 449 insomnia patients and 357 healthy controls, found consistent evidence of elevated 24-hour cortisol activity in chronic insomnia patients — a signature of persistent HPA axis dysregulation rather than simply a circadian timing problem.[2]

Ashwagandha's withanolide compounds appear to modulate this cascade at the hypothalamic level, influencing CRH signalling and thereby reducing the downstream cortisol output. This is the mechanism through which ashwagandha is believed to address stress-driven sleep disruption: not by overriding the arousal state, but by reducing the signal that is driving it.

What do the clinical trials actually show?

The most robust current synthesis of the ashwagandha-sleep evidence is the 2021 meta-analysis in *PLOS ONE* by Kae Ling Cheah and colleagues at Universiti Sains Malaysia.[1] The authors pooled five randomised controlled trials with 400 participants, assessing sleep outcomes using validated instruments including the Pittsburgh Sleep Quality Index (PSQI), actigraphy, and the Insomnia Severity Index. The primary finding was a standardised mean difference of -0.59 (95% CI -0.75 to -0.42) for overall sleep quality — a statistically significant, small-to-moderate effect. Importantly, this estimate represents the average across all five trials and should be interpreted in context: effects were considerably larger in participants with insomnia diagnoses than in healthy volunteers, and in trials using higher doses and longer durations.

Two individual trials from this evidence base deserve attention. The first is a double-blind, randomised, placebo-controlled study by Langade and colleagues, published in *Cureus* in 2019, involving 60 adults with insomnia.[3] Participants received 300 mg of KSM-66 ashwagandha root extract twice daily (600 mg total) for ten weeks. Actigraphy measurements showed statistically significant improvements in sleep onset latency — the time to fall asleep — total sleep time, sleep efficiency, and wake after sleep onset compared to placebo. This is an important trial because it used objective actigraphy rather than relying solely on self-report, which is a more rigorous measurement approach for sleep outcomes.

The second is a parallel-group, double-blind, placebo-controlled study by the same research group, published in the *Journal of Ethnopharmacology* in 2021, which extended the investigation to include both adults with insomnia and healthy volunteers.[4] At 600 mg per day for eight weeks, sleep quality improvements were observed across both populations, though the effect was larger and more consistent in the insomnia subgroup. This pattern — greater benefit in people whose sleep is already disrupted — is biologically coherent: ashwagandha is addressing a dysfunction, and the more significant the dysfunction, the more room there is for improvement.

It is important to note that several of the clinical trials in this area have been conducted using manufacturer-supplied KSM-66 extract, and some studies have been run by research groups with institutional connections to the producer. This is a common pattern in botanical research and does not automatically invalidate the findings, but it is the reason the meta-analytic evidence across multiple trials should carry more weight than any single trial in isolation. The heterogeneity across studies is relatively low, which adds confidence to the pooled estimate.

How does ashwagandha compare to melatonin for sleep?

The most directly relevant comparative data comes from a 2025 prospective, randomised, double-blind, placebo-controlled trial that assigned 200 adults aged 18–50 to receive ashwagandha root extract (300 mg twice daily), melatonin (3 mg daily), a combination of both, or placebo for eight weeks.[5] The primary outcome was change in sleep onset latency measured by actigraphy. The combination arm produced the strongest effects; both ashwagandha and melatonin individually outperformed placebo on sleep onset latency, with similar effect sizes between the two single-ingredient arms.

This trial warrants a note of caution: as of the time of writing, it has not completed peer review in a major journal, and it originates from a research group with established ties to the KSM-66 manufacturer. Treat its findings as preliminary rather than definitive. What it does usefully illustrate is the mechanistic distinction between the two approaches: melatonin addresses circadian timing; ashwagandha addresses the arousal state. In populations where both are disrupted — a stressed individual with both elevated cortisol and a shifted sleep-wake phase — the combination produces additive benefit. For someone whose problem is primarily stress-driven hyperarousal, ashwagandha is the more targeted intervention.

What about the GABAergic mechanism?

Cortisol regulation is not ashwagandha's only route to improved sleep. Preclinical research has identified triethylene glycol, a non-withanolide component of ashwagandha root extract, as a sleep-inducing compound with activity at GABAergic pathways.[6] GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter; GABAergic signalling reduces neuronal excitability and is central to the physiological transition from wakefulness into sleep. This is the same broad pathway engaged by pharmaceutical sedatives and some prescription hypnotics — though ashwagandha's activity at this system is far more modest and does not carry the risk of dependence or next-day sedation associated with those drug classes.

The dual mechanism — HPA axis modulation and GABAergic calming — may explain why ashwagandha influences multiple sleep parameters rather than just one, and why its effects appear across both sleep onset and sleep maintenance measures in the trial data.

What dose of ashwagandha is supported by the evidence for sleep?

The clinical evidence is clearest at 600 mg per day of a standardised ashwagandha root extract, divided as 300 mg twice daily, for a minimum of eight weeks. The 2021 meta-analysis subgroup analysis found meaningfully larger effects at this dose threshold compared to lower doses.[1] The standardisation of the extract matters: KSM-66 (standardised to ≥5% withanolides) and Sensoril (standardised to ≥10% withanolides, from root and leaf) are the two extracts with the most human clinical trial data.

How long it takes to work is a question that requires an honest answer: expect nothing significant in the first two to four weeks. The HPA axis recalibration that drives ashwagandha's sleep benefit is a gradual process. Some people report earlier improvements in subjective stress and mental alertness — which may itself improve the conditions for sleep — but the sleep-specific benefit in the published trials typically becomes measurable from week six to eight onwards. Expecting immediate results with ashwagandha will almost always lead to early discontinuation before the effect window is reached.

Who is most likely to benefit?

The evidence is most robust for adults with stress-related insomnia — people whose sleep is disrupted by chronic psychological stress, HPA axis dysregulation, or the cortisol-driven hyperarousal that characterises the "wired but tired" experience. The effect in healthy sleepers without significant sleep complaints is smaller and less consistent, though not absent. People in physically demanding recovery contexts — athletes with high training loads and disrupted sleep — represent another well-studied population with relevant data.

People with diagnosed thyroid disorders (particularly hypothyroidism), autoimmune conditions, or those taking immunosuppressant medication should consult a healthcare professional before using ashwagandha, as it may have thyroid-stimulating effects and immunomodulatory activity that could interact with these conditions. Ashwagandha should not be used during pregnancy.

Rare cases of hepatotoxicity (liver injury) have been reported in the literature, though establishing causality in individual cases is difficult. The established clinical trials at doses of 300–600 mg per day for up to 16 weeks have not reported significant liver safety signals, but anyone who develops unexplained fatigue, jaundice, or abdominal discomfort while taking ashwagandha should discontinue and seek medical review.

How ashwagandha fits into ARC's three-pillar formulation

In ARC, ashwagandha is the stress-axis ingredient — the one responsible for the slow, cumulative work of reducing HPA axis hyperactivation that underpins chronic sleep disruption. It works alongside magnesium bisglycinate (parasympathetic nervous system support), L-theanine (cognitive hyperarousal reduction), apigenin (GABA-A receptor activity), and P5P, the active form of vitamin B6 that serves as the rate-limiting cofactor in the enzymatic conversion of serotonin to melatonin. Each ingredient is addressing a different element of the sleep-stress-recovery cycle; ashwagandha's contribution is the one that takes longest to manifest, but it is also the one targeting the deepest mechanism.

The 300 mg dose used in ARC (twice daily, for a total of 600 mg) is the dose used in the most robust clinical trials and sits at the threshold the meta-analysis identified as producing the most consistent effects. It is not an arbitrary marketing figure — it is the closest available approximation to what the published RCTs used, at the same standardised extract, at the same daily total.

FAQ

How long does ashwagandha take to improve sleep?
Based on the clinical trial evidence, meaningful improvements in sleep quality are most consistently observed after eight weeks of daily use at 600 mg per day of a standardised extract. The 2021 meta-analysis found effects were most pronounced at treatment durations of eight weeks or longer. Some people notice earlier changes in subjective stress and daytime alertness — which can indirectly improve sleep conditions — but the specific sleep benefit accumulates gradually rather than appearing after a single dose.

Does ashwagandha cause drowsiness or grogginess?
No — not in the manner of a sedative. Ashwagandha does not directly inhibit the central nervous system in the way that pharmaceutical hypnotics or antihistamine-based sleep aids do. People who notice drowsiness in the first few days of use are likely experiencing relaxation rather than sedation. The clinical trials consistently report no significant impairment of next-day alertness, and several specifically measured mental alertness on rising as an outcome, finding it improved rather than reduced with ashwagandha use.

*This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your supplement routine.*

Written by Cameron Webb, MPharm, PhD — Pharmacist and Founder of NutraWebb

References

1. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (*Withania somnifera*) extract on sleep: A systematic review and meta-analysis. *PLOS ONE.* 2021;16(9):e0257843. doi:10.1371/journal.pone.0257843. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462692/

2. Dressle RJ, Feige B, Spiegelhalder K, et al. HPA axis activity in patients with chronic insomnia: A systematic review and meta-analysis of case-control studies. *Sleep Med Rev.* 2022;62:101588. doi:10.1016/j.smrv.2022.101588. PMID: 35091194. https://pubmed.ncbi.nlm.nih.gov/35091194/

3. Langade D, Kanchi S, Salve J, et al. Efficacy and Safety of Ashwagandha (*Withania somnifera*) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. *Cureus.* 2019;11(9):e5797. doi:10.7759/cureus.5797. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827862/

4. Langade D, Thakare V, Kanchi S, Kelgane S. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study. *J Ethnopharmacol.* 2021;264:113276. doi:10.1016/j.jep.2020.113276. PMID: 32818573. https://pubmed.ncbi.nlm.nih.gov/32818573/

5. Andrade C et al. Comparative Evaluation of Ashwagandha (*Withania somnifera*) Root Extract and Melatonin for Improving Sleep Quality in Adults: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. PMC13108063. [Preprint — not yet peer-reviewed in a major journal as of May 2026.] https://pmc.ncbi.nlm.nih.gov/articles/PMC13108063/

6. Kaushik MK, Kaul SC, Wadhwa R, et al. Triethylene glycol, an active component of Ashwagandha (*Withania somnifera*) leaves, is responsible for sleep induction. *PLOS ONE.* 2017;12(2):e0172508. doi:10.1371/journal.pone.0172508